Relating CYP2B6 genotype and efavirenz resistance among post-partum women living with HIV with high viremia in Uganda: a nested cross-sectional study [0.03%]
乌干达高病毒血症的艾滋病毒感染产妇中的CYP2B6基因型与依非韦伦耐药性：巢式横断面研究
Allan Buzibye,Kara Wools-Kaloustian,Adeniyi Olagunju et al.
Allan Buzibye et al.
Sanger sequencing was used to detect resistant mutations, as well as host genotyping, and efavirenz resistance was compared among the metabolizer genotypes.
Antiretroviral drug resistance mutations among patients failing first-line treatment in Hanoi, Vietnam [0.03%]
越南河内一线治疗失败患者的抗逆转录病毒药物耐药性突变情况
Tran Viet Tien,Dinh Cong Pho,Le Thu Hong et al.
Tran Viet Tien et al.
In NNRTIs, the prevalence of nevirapine resistance was 55.8%, and that of efavirenz resistance was 4.7%. In NRTIs, the ratio of lamivudine resistance was 93.0%, and that of zidovudine resistance was 9.3%. No lopinavir/ritonavir resistance was recorded.
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients [0.03%]
治疗初治的人免疫缺陷病毒(HIV)-1感染者中少见多拉韦林抗药性相关突变体
Cathia Soulie,Maria Mercedes Santoro,Charlotte Charpentier et al.
Cathia Soulie et al.
In comparison, the prevalence of rilpivirine, etravirine, nevirapine and efavirenz resistance was higher whatever algorithm was used (ANRS: 8.5%, 8.1%, 8.3% and 3.9%, respectively; Stanford: 9.9%, 10.0%, 7.5% and 9.4%, respectively).
HIV pretreatment drug resistance trends in three geographic areas of Mexico [0.03%]
墨西哥三个地区的HIV耐药预处理流行趋势分析
Claudia García-Morales,Daniela Tapia-Trejo,Verónica S Quiroz-Morales et al.
Claudia García-Morales et al.
For 2008-16, we observed increasing efavirenz resistance trends in all regions (P < 0.05, all cases), reaching 11.8%, 6.1% and 8.3% respectively in 2016....Increasing efavirenz resistance was mostly associated with increasing K103N frequency (P = 0.007 CMZ, P = 0.03 Tijuana, not significant for Cancun)....Even when increasing trends in efavirenz resistance were observed in the three areas, our observations support that, in a large country such as Mexico, subnational surveillance and locally tailored interventions to address drug resistance may be a reasonable option.
A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses [0.03%]
俄罗斯A亚型人免疫缺陷病毒中普遍存在的一种独特的非核苷逆转录酶抑制剂抗性突变体
Anna N Kolomeets,Vici Varghese,Philippe Lemey et al.
Anna N Kolomeets et al.
Conclusion: The predisposition of subtype A(FSU) to G190S is concerning because G→A is the most common HIV-1 mutation and because G190S causes higher levels of nevirapine and efavirenz resistance than K103N.
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases [0.03%]
异基因干细胞移植后不使用抗逆转录病毒的HIV-1缓解和反弹：两例报告
Timothy J Henrich,Emily Hanhauser,Francisco M Marty et al.
Timothy J Henrich et al.
One patient developed new efavirenz resistance after reinitiation of antiretroviral therapy. Reinitiation of active therapy led to viral decay and resolution of symptoms in both patients.
Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda [0.03%]
乌干达一线高效抗逆转录病毒疗法失败后的耐药性演变路径及机制研究
Steven J Reynolds,Cissy Kityo,Frank Mbamanya et al.
Steven J Reynolds et al.
Results: All patients receiving efavirenz-containing HAART had > or =1 efavirenz resistance mutation develop during follow-up.
Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V [0.03%]
具有EFV抗性的HIV-1突变体的相对复制适应度：与临床治疗期间频率的相关性以及核苷酸耐药突变L74V补偿K103N+L100I所降低的适应度的证据
Christine E Koval,Carrie Dykes,Jiong Wang et al.
Christine E Koval et al.
We hypothesized that differences in replication efficiency, or fitness, influence the relative frequencies of these secondary efavirenz resistance mutations in clinical isolates....Our studies suggest the primary driving force behind the selection of secondary efavirenz resistance mutations is the acquisition of higher levels of drug resistance, but the specific secondary mutations to emerge are those with the least cost in terms of replication efficiency.
Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine [0.03%]
从奈韦拉平治疗失败的患者体内检测少数HIV-1株系中的K103N耐药突变体
Denise Lecossier,Nancy S Shulman,Laurence Morand-Joubert et al.
Denise Lecossier et al.
Salvage therapy with efavirenz is often ineffective in patients having failed nevirapine treatment, even when mutations associated with efavirenz resistance are not detected by standard population-based genotyping.
Extent and importance of cross-resistance to efavirenz after nevirapine failure [0.03%]
尼维拉平治疗失败后对依发韦仑交叉耐药的情况及其重要性
Jose L Casado,Ana Moreno,Kurt Hertogs et al.
Jose L Casado et al.
A previous longer period of nevirapine therapy was significantly associated with the emergence of efavirenz resistance (288 vs. 170 days, p < 0.01).
耗时 0.11666 秒，为您在
48223910
条记录里面共找到 11 篇文章 [XML]